139 related articles for article (PubMed ID: 32725531)
1. ASO Author Reflections: Characterizing the Impact of RAS Mutation Location on Outcomes for Colorectal Liver Metastases.
Saadat LV; D'Angelica MI
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):867-868. PubMed ID: 32725531
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Can We Predict an Unsalvageable Recurrence Following Colorectal Liver Metastasectomy?
Okuno M; Conrad C
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):549-550. PubMed ID: 30565037
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Poorest Survival Outcomes in Patients with Right Colon Cancer with KRAS Mutation After Simultaneous Curative-Intent Surgery for Colorectal Cancer Liver Metastases.
Kim HS; Kim NK
Ann Surg Oncol; 2020 Dec; 27(13):5159-5160. PubMed ID: 32813206
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into "Precision Oncosurgery" in Colorectal Liver Metastases.
Kobayashi S; Takahashi S; Yoshino T; Taniguchi H
Ann Surg Oncol; 2020 Sep; 27(9):3316-3317. PubMed ID: 32642996
[No Abstract] [Full Text] [Related]
5. Tailoring ablation strategies for colorectal liver metastases based upon rat sarcoma viral oncogene mutation status.
Calandri M; Odisio BC
Chin Clin Oncol; 2019 Oct; 8(5):51. PubMed ID: 31500432
[TBL] [Abstract][Full Text] [Related]
6. ASO Author Reflections: RAS Mutations in Metastatic Colorectal Cancer.
Passot G; Vauthey JN; Chun YS
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):850-851. PubMed ID: 30421059
[No Abstract] [Full Text] [Related]
7. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
8. K-Ras and MSI: potential markers of both patient prognosis and treatment efficacy.
Turaga K; Shibata D
Ann Surg Oncol; 2010 Feb; 17(2):354-5. PubMed ID: 19936842
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Tending Towards a Personalized Medicine for Colorectal Carcinomatosis by Adding the RAS Mutation Status in the Workup for CRS and HIPEC.
Arjona-Sanchez A; Rodriguez-Ortiz L
Ann Surg Oncol; 2019 Aug; 26(8):2605-2606. PubMed ID: 31004296
[No Abstract] [Full Text] [Related]
10. RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.
Brudvik KW; Jones RP; Giuliante F; Shindoh J; Passot G; Chung MH; Song J; Li L; Dagenborg VJ; Fretland ÅA; Røsok B; De Rose AM; Ardito F; Edwin B; Panettieri E; Larocca LM; Yamashita S; Conrad C; Aloia TA; Poston GJ; Bjørnbeth BA; Vauthey JN
Ann Surg; 2019 Jan; 269(1):120-126. PubMed ID: 28549012
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
[TBL] [Abstract][Full Text] [Related]
13. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
Jácome AA; Vreeland TJ; Johnson B; Kawaguchi Y; Wei SH; Nancy You Y; Vilar E; Vauthey JN; Eng C
Br J Cancer; 2021 Feb; 124(4):797-804. PubMed ID: 33208919
[TBL] [Abstract][Full Text] [Related]
15. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
[TBL] [Abstract][Full Text] [Related]
16. Interactions of multiple gene alterations in colorectal liver metastases.
Kawaguchi Y; Velasco JD; Arvide EM; Wei SH; Vauthey JN
Chin Clin Oncol; 2019 Oct; 8(5):50. PubMed ID: 31500427
[TBL] [Abstract][Full Text] [Related]
17. From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS.
Vauthey JN; Kopetz SE
Cancer; 2013 Dec; 119(23):4083-5. PubMed ID: 24105015
[No Abstract] [Full Text] [Related]
18. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A
Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399
[TBL] [Abstract][Full Text] [Related]
19. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.
Schimanski CC; Moehler M; Gockel I; Zimmermann T; Lang H; Galle PR; Berger MR
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1139-45. PubMed ID: 21468700
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
